Holds one active US DMF and 2 valid CEPs for bisoprolol, filing since 2013. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.
Holds one active US DMF and 2 valid CEPs for bisoprolol, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.
Holds one active US DMF and one valid CEP for bisoprolol, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Holds one active US DMF and one valid CEP for bisoprolol, filing since 2021. Its 2024 FDA inspection closed as VAI.
Holds one valid CEP for bisoprolol, filing since 2024. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds one valid CEP for bisoprolol, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 3 markets.
Holds one valid CEP for bisoprolol, filing since 2022. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 11 markets.
Holds one active US DMF and one valid CEP for bisoprolol, filing since 2005. Its 2025 FDA inspection closed as VAI.
Holds 2 active US DMFs for bisoprolol, filing since 2021. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for bisoprolol, filing since 2025. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one valid CEP for bisoprolol, filing since 2025. Its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Bisoprolol manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free